TRAW insider buying and SEC filings, explained
Traws Pharma, Inc. · CIK 1130598
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$998K
Insiders who bought
1
Sold (not marked 10b5-1)
$0
Planned sales (10b5-1)
$0
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Apr 16, 2026 | Other purchase | ORBIMED ADVISORS LLC (10% owner) bought 2,988,645 shares in 3 share classes indirectly; the filing does not report a price. New position of 1,793,187 shares. Not marked as a 10b5-1 plan trade. Filed jointly with 1 other reporting owner. | SEC filing Filed Apr 28, 2026 |
| Apr 16, 2026 | Purchase (code P) | ORBIMED ADVISORS LLC (10% owner) bought 597,729 shares indirectly at $1.67 ($998K), reported as a purchase (code P). Indirect holdings up 99% to 1,203,250 shares. Not marked as a 10b5-1 plan trade. Filed jointly with 1 other reporting owner. | SEC filing Filed Apr 28, 2026 |
30 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow TRAW in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.